Trials / Completed
CompletedNCT01615198
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 588 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to access the efficacy and safety of LCZ696 compared to olmesartan in elderly Asian patients for the treatment of hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olmesartan | 10 mg, 20 mg, 40 mg capsules |
| DRUG | Placebo | Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule |
| DRUG | LCZ696 | 100 mg, 200 mg tablets |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2012-06-08
- Last updated
- 2015-10-23
- Results posted
- 2015-08-18
Locations
79 sites across 7 countries: China, Hong Kong, Japan, Philippines, South Korea, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT01615198. Inclusion in this directory is not an endorsement.